Biotech firm Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to ...

Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...

In principle, mRNA vaccines are ideal for health emergencies as they can be quickly mass produced using a template. The problem is that current cell-based template production methods take too long, ...

A complex molecular machine, the spliceosome, ensures that the genetic information from the genome, after being transcribed ...

A complex molecular machine, the spliceosome, ensures that the genetic information from the genome, after being transcribed ...

Moderna shares recovered from an early dip premarket despite the biotech's quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, or $2 ...

While some of the initial zeal around localized vaccine production in Africa has waned since the height of the COVID-19 ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

In a landmark achievement for both Uganda and the global medical community, the United States Patent and Trademark Office ...

The deal is analogous to the UK's earlier decade-long agreement with Moderna, which centred on a manufacturing facility for mRNA vaccines, mainly targeting infectious diseases, along with R&D ...

Shares of Moderna, along with other vaccine makers, dropped further this year as lawmakers advanced President Donald Trump's ...